IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?

被引:12
|
作者
Brugnano, R. [1 ]
Del Sordo, R. [2 ]
Covarelli, C. [2 ]
Gnappi, E. [3 ]
Pasquali, S. [3 ]
机构
[1] Osped S Maria Misericordia, Dept Nephrol & Dialysis, Piazza Menghini 1, I-06156 Perugia, Italy
[2] Univ Perugia, Sch Med, Dept Expt Med, Sect Pathol Anat & Histol, Perugia, Italy
[3] Santa Maria Nuova Hosp, UOC Nephrol & Dialysis, Reggio Emilia, Italy
关键词
IgM nephropathy; Minimal change disease; Focal segmental glomerulosclerosis; Nephrotic syndrome; Controversy; MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS; IMMUNOGLOBULIN-M NEPHROPATHY; IDIOPATHIC NEPHROTIC SYNDROME; GLOMERULAR-DISEASE; LONG-TERM; NATURAL-HISTORY; SINGLE-CENTER; FOLLOW-UP; DEPOSITS; CHILDREN;
D O I
10.1007/s40620-016-0269-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Immunoglobulin (Ig)M nephropathy (IgMN), known since 1978, is a very controversial clinicopathological entity characterized by IgM diffuse deposits in the mesangium at immunofluorescence whereas light microscop identifies minimal glomerular lesion, hypercellularity and expansion of the mesangium or sclerotic focal, segmental lesion. Clinically, it is a nephrotic syndrome, especially in pediatric patients, or asymptomatic proteinuria and/or isolated hematuria. These characteristics narrowly define IgMN between minimal change disease and focal segmental glomerulosclerosis, so it is not often recognized as a separate pathology. Homogeneous epidemiologic, pathogenetic, clinical or histological data are not available. Recent research on the pathogenetic role of mesangial IgM has, however, renewed interest in IgMN and naturally the controversies.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 50 条
  • [1] IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?
    R. Brugnano
    R. Del Sordo
    C. Covarelli
    E. Gnappi
    S. Pasquali
    Journal of Nephrology, 2016, 29 : 479 - 486
  • [2] Minimal change nephropathy and focal segmental glomerulosclerosis
    Peter W. Mathieson
    Seminars in Immunopathology, 2007, 29 : 415 - 426
  • [3] Minimal change nephropathy and focal segmental glomerulosclerosis
    Mallick, NP
    Brenchley, PEC
    Webb, NJA
    KIDNEY INTERNATIONAL, 1997, : S80 - S82
  • [4] Minimal change nephropathy and focal segmental glomerulosclerosis
    Mathieson, Peter W.
    SEMINARS IN IMMUNOPATHOLOGY, 2007, 29 (04) : 415 - 426
  • [5] The treatment of minimal change nephropathy and focal segmental glomerulosclerosis
    Milford, D
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON, 1997, 31 (04): : 468 - 468
  • [6] The treatment of minimal change nephropathy and focal segmental glomerulosclerosis
    Mason, PD
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON, 1997, 31 (02): : 137 - 141
  • [7] Minimal change disease and focal segmental glomerulosclerosis
    Fogo, AB
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 : 74 - 76
  • [8] Minimal change disease and focal segmental glomerulosclerosis
    Osterholt, Thomas
    Benzing, Thomas
    Brinkkoetter, Paul Thomas
    NEPHROLOGIE, 2025, 20 (01): : 18 - 25
  • [9] Minimal change disease and focal segmental glomerulosclerosis
    Mueller-Deile, J.
    Schenk, H.
    Schiffer, M.
    INTERNIST, 2019, 60 (05): : 450 - 457
  • [10] Rituximab in minimal change disease and focal segmental glomerulosclerosis
    Kronbichler, Andreas
    Gauckler, Philipp
    Bruchfeld, Annette
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (06) : 983 - 985